Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

1.00
-0.0100-0.99%
Post-market: 0.9899-0.0101-1.01%18:31 EDT
Volume:276.54K
Turnover:277.14K
Market Cap:36.65M
PE:-2.81
High:1.03
Open:1.03
Low:0.9701
Close:1.01
52wk High:1.45
52wk Low:0.7006
Shares:36.65M
Float Shares:30.09M
Volume Ratio:0.42
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3554
EPS(LYR):-0.3958
ROE:-146.61%
ROA:-68.39%
PB:4.54
PE(LYR):-2.53

Loading ...

RenovoRx to host Q4 and full-year 2025 financial results conference call

Reuters
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies

Reuters
·
Mar 19

BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist

Reuters
·
Mar 18

BUZZ-RenovoRx rises after $10 mln private stock sale to fund cancer trial, device rollout

Reuters
·
Mar 18

BRIEF-Renovorx Announces $10 Million At Market Private Placement

Reuters
·
Mar 18

RenovoRx announces USD 10 million private placement of common stock and warrants

Reuters
·
Mar 18

RenovoRx Inc - to Issue 10.6 Mln Shares at $0.938 per Share With 50% Warrant Coverage

THOMSON REUTERS
·
Mar 18

RenovoRx Names Ramtin Agah Executive Chairman

Reuters
·
Feb 27

RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

GlobeNewswire
·
Feb 27

RenovoRx to Present TAMP Therapy Platform Pancreatic Cancer PET/CT Findings at 2026 Society of Interventional Radiology Annual Scientific Meeting

Reuters
·
Feb 26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)

TIPRANKS
·
Feb 18

RenovoRx Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Feb 17

BRIEF-Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives

Reuters
·
Feb 10

RenovoRx - Formation of Renovocath Medical Advisory Board to Support Clinical and Strategic Initiatives

THOMSON REUTERS
·
Feb 10

Press Release: RenovoRx Establishes RenovoCath(R) Medical Advisory Board

Dow Jones
·
Feb 10

RenovoRx appoints Voll as Chief Financial Officer

TIPRANKS
·
Feb 05

RenovoRx Names Mark Voll Chief Financial Officer

Reuters
·
Feb 05

Press Release: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

Dow Jones
·
Feb 05

RenovoRx Unveils Clinical Data Supporting TAMP Therapy Platform at SIO 2026 Meeting

Reuters
·
Feb 04

RenovoRx Announces Clinical Data Supporting the Tamp™ Therapy Platform Will Be Presented at the Sio 2026 Annual Scientific Meeting

THOMSON REUTERS
·
Feb 04